ALT

Altimmune, Inc. (ALT) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company has not generated revenue from product sales to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Increased by $2.4 million (11%) to $24.2 million. Research and Development (R&D) expenses rose slightly by 2% to $16.2 million, driven by ongoing ALD and AUD trials and startup costs for the PERFORMA Phase 3 MASH trial, partially offset by the completion of the IMPACT Phase 2b trial. General and Administrative (G&A) expenses increased 34% to $8.1 million, primarily due to a $1.3 million increase in compensation (including $0.6 million in severance) and higher professional fees.
• Net Loss: Increased by $3.0 million (15%) to $22.6 million. This was driven by higher operating expenses and interest expense of $1.1 million (vs. negligible in prior year), partially offset by a significant increase in interest income ($2.9 million vs. $1.5 million).
• Cash Flow: Net cash used in operating activities increased to $20.9 million (from $16.8 million). Net cash provided by financing activities surged to $78.5 million (from $34.1 million), driven by a $70.3 million Registered Direct Offering (RDO) in January 2026 and $8.7 million from At-The-Market (ATM) offerings.
• Impairment: Recognized a $0.7 million impairment charge related to office and laboratory lease assets.

Outlook, Guidance, and Risks

• Clinical Progress:
  • MASH: Received FDA Breakthrough Therapy Designation in January 2026. Positive 48-week data from the IMPACT trial announced. The PERFORMA Phase 3 trial is in the startup phase, with initiation planned for the second half of 2026.
  • AUD: Enrollment for the RECLAIM Phase 2 trial completed in November 2025. Topline results expected in Q3 2026.
  • ALD: Enrollment for the RESTORE Phase 2 trial is expected to complete in Q3 2026.
• Capital Resources: Management believes current cash, cash equivalents, and short-term investments ($331.5 million as of March 31, 2026), combined with proceeds from a subsequent April 2026 offering, are sufficient to fund operations for at least 12 months.
• Subsequent Financing: On April 22, 2026, the company completed an underwritten public offering raising approximately $211.2 million in net proceeds. This included common stock, pre-funded warrants, and accompanying warrants. Full exercise of warrants could yield an additional $225 million.
• Risks: The company faces risks related to the success of clinical trials, regulatory approval, and the need for additional capital. Global economic factors, including tariffs and the conflict in the Middle East, may impact costs and supply chains.

Key Investor Verification Points

• Capital Runway: Verify the impact of the $211.2 million April 2026 offering on the company's cash runway and ability to fund the PERFORMA Phase 3 trial without further dilution.
• Dilution: Assess the dilutive impact of the January 2026 RDO, April 2026 offering, and outstanding options/RSUs (12.1 million options and 2.2 million RSUs outstanding as of March 31, 2026).
• Debt Covenants: Monitor compliance with the Hercules Capital Term Loan covenants, specifically the market capitalization threshold ($800 million) for conditional waivers.
• Clinical Milestones: Track the initiation of the PERFORMA Phase 3 trial in H2 2026 and the Q3 2026 topline data release for the AUD trial.
• Expense Management: Review the trajectory of G&A expenses following the one-time severance costs and the ramp-up of Phase 3 trial costs.